2. Liu Z, Huang Q, Ding M, Wang T, Chen Y, Zhang K. BRCA2 mutations in familial breast cancer with prostate cancer: a case report and literature review. Front Oncol. 2024 Sep 19;14:1428849. doi: 10.3389/fonc.2024.1...
[3]Oh M, Alkhushaym N, Fallatah S, et al. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis. Prostate. 2019;79(8):880-895. doi:10.1002/pros.23795 [4]Hu C, Hart SN, Polley EC, et al. Association Between Inherited Ge...
Castro E, Eeles R: The role of BRCA1 and BRCA2 in prostate cancer. Asian J Androl 14: 409-414, 2012Castro E, Eeles R. The role of BRCA1 and BRCA2 in prostate cancer. Asian J Androl 2012;14:409-14.Castro E,Eeles R.The role of BRCA1and BRCA2in prostate cancer. Asian ...
[3] RB1 and TP53 Loss Promotes Lineage Plasticity in Prostate Cancer. Cancer Discovery, 2017, 7(3):244. [4] Chen M, Zhang J, Sampieri K, et al. An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer. Nature Geneti...
BRCA1 and BRCA2 pathogenic variants (PVs) are associated with prostate cancer (PCa) risk, but a wide range of relative risks (RRs) has been reported. We systematically searched PubMed, Embase, MEDLINE and Cochrane Library in June 2021 for studies that es
[3]Oh M, Alkhushaym N, Fallatah S, et al. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis. Prostate. 2019;79(8):880-895. doi:10.1002/pros.23795 [4]Hu C, Hart SN, Polley EC, et al. Association Between Inherited Ge...
19、te cancer with brca1 and brca2 founder mutationsj.clinical cancer research,2009,15(3):1112-1120.7 oh m,alkhushaym n,fallatah s,et al.the association of brca1 and brca2 mutations with prostate cancer risk,frequency,and mortality:a meta-nalysisj.the prostate,2019,79(8):880-895.8 try...
Tanaka H, Yoshida S, Aoyama S, Ikeda S, Kunieda J, Ohashi K, Fukuda S, Waseda Y, Tanaka H, Fujii Y. A case of double-negative prostate cancer with BRCA2 mutation and high tumor mutation burden treated sequentially with olaparib and pembrolizumab. IJU Case Rep. 2024 Aug 4;7(5):395-...
Tanaka H, Yoshida S, Aoyama S, Ikeda S, Kunieda J, Ohashi K, Fukuda S, Waseda Y, Tanaka H, Fujii Y. A case of double-negative prostate cancer with BRCA2 mutation and high tumor mutation burden treated sequentially with olaparib and pembrolizumab. IJU Case Rep. 2024 Aug 4;7(5):395-...
Omura M, Kosaka T, Aimono E, Nakamura K, Hongo H, Mikami S, Nishihara H, Oya M. First successful case of platinum-based chemotherapy for neuroendocrine prostate cancer with BRCA2 and PTEN alterations. IJU Case Rep. 2021 Oct 20;5(1):41-44. doi: 10.1002/iju5.12383. PMID: 35005470; PM...